Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2019

View Archived Issues

High-throughput, low-stress analysis method separates out brain cells

Prostate cancer cell lineage switch identified

Procarta Biosystems announces funding for development of new class of antibiotic precision medicines

CROI 2019: KSHV targeting may move from lytic to latent phase

Sf3b1 gene mutation with Atm gene deletion yields new model of chronic lymphocytic leukemia

Phase III studies of triple combination of VX-445, tezacaftor and ivacaftor meet primary endpoint

Santen launches two new research and development projects selected for the CiCLE program

Transgene plans clinical development of individualized immunotherapy TG-4050

FDA approves IND for phase I trials of NK cell adoptive immunotherapy candidate SNK-01

Intarcia opts to inlicense ND-016 from Numab Therapeutics

Novel selective inhibitor of the RUVBL1/2 complex demonstrates anticancer activity in vivo

VU-6012962 results in decreased anxiety response in preclinical models

I-Mab Biopharma begins phase Ib/IIa study of TJ-107 in China

Acesion Pharma divulges SK3 blockers

XW Laboratories discloses ROS production inhibitors

JAK and/or SYK kinase inhibitors disclosed by Beijing Hanmi Pharmaceutical

Zhejiang Hisun Pharmaceutical describes KIT and PDGFR-alpha mutant inhibitors

Bifunctional TFR1 ligand-peptides as erythroblast-targeted gene therapy for erythroid disorders

SHR-A1403 antibody-drug conjugate, a potential therapy for cancers with c-Met overexpression

Combined use of DREP-based vectors and MVA-HCV as promising vaccines against HCV

Chinese researchers patent 5-HT1A receptor agonists

Glycopeptide derivative of angiotensin-(1-7) reverses cognitive dysfunction in mice models of VCID

DS Biopharma reports promising data on DS-107 cream in moderate to severe atopic dermatitis

Three pivotal studies of rapastinel in adjunctive treatment of MDD miss primary endpoint

Completion of phase Ia study of FOR-6219 for endometriosis paves way for phase Ib

Immutep reports new data from phase I TACTI-mel study of eftilagimod alpha in melanoma